AstraZeneca PLC (AZN)vsVicarious Surgical Inc. (RBOT)
AZN
AstraZeneca PLC
$185.95
-1.94%
HEALTHCARE · Cap: $282.69B
RBOT
Vicarious Surgical Inc.
$0.69
+3.78%
HEALTHCARE · Cap: $7.07M
Smart Verdict
WallStSmart Research — data-driven comparison
AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
RBOT
Avoid23
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for RBOT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : RBOT
The strongest argument for RBOT centers on Price/Book.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : RBOT
The primary concerns for RBOT are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
AZN profiles as a mature stock while RBOT is a value play — different risk/reward profiles.
RBOT carries more volatility with a beta of 1.82 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 23/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Vicarious Surgical Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Vicarious Surgical Inc. (RBOT) is an innovative medical technology firm that is transforming surgical procedures through its state-of-the-art robotic surgical systems. By harnessing a proprietary platform that combines advanced robotics and artificial intelligence, Vicarious Surgical pioneers minimally invasive surgery, enhancing surgeons' precision, control, and visualization. The company's commitment to improving surgical efficiency and reducing patient recovery times positions it as a key player in the expanding surgical robotics market, addressing the growing demand for effective robotic-assisted interventions in modern healthcare. With a strong focus on innovation, Vicarious Surgical is dedicated to advancing patient care and outcomes in a rapidly evolving medical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?